Innovent Biologics Targets Total Revenue of RMB 35 Billion–40 Billion by 2030

By Public Technologies
  • Innovent Biologics targets total revenue of RMB 35 billion to RMB 40 billion by 2030, with profit margins benchmarked against top-tier pharmaceutical companies.
  • Strategic goals include advancing at least five molecules into global multi-regional Phase 3 development by 2030, with launches in key US and European markets.
  • Third-quarter 2026 product revenue exceeded RMB 4.7 billion, up over 40% year over year, supported by general biomedicine expansion and oncology sales growth.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261029-12386909), on October 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk